Influential black figures have joined forces to speak out about a deadly disease that sees black men twice at risk compared to white men.Read the full story ›
Scientists were astounded by the results of the experimental therapy, which involves shocking tumours to death with testosterone.Read the full story ›
Number of deaths caused by prostate cancer "could rise by a third" by 2026 unless urgent action is taken now, a leading charity has warned.Read the full story ›
A British man has been praised after a photo he posted to raise awareness of prostate cancer was shared thousands of times.Read the full story ›
Five different recipes of prostate cancer have been identified, with major implications for the way the disease is treated.Read the full story ›
A drug to combat advanced prostate cancer will not be provided on the NHS because it is not 'cost-effective'Read the full story ›
Prince Harry embraced the macho image of the City trading floor today when he made a grab for a male broker dressed as the character Heidi.Read the full story ›
Prostate cancer patients' charity Tackle has welcomed health watchdog Nice's draft approval of making a life-extending drug available on the NHS.
A spokesman for the charity said:
This offers a vital lifeline to thousands of men facing death sentences due to the very limited options for treatment if chemotherapy has failed.
Enzalutamide has shown great success treating men with advanced prostate cancer beyond the stage at which conventional hormone treatment or docetaxel chemotherapy is effective.
Health officials have given a life-extending drug the green light for widespread NHS, giving hope to thousands of men facing a "death sentence" from prostate cancer.
The National Institute for Health and Care Excellence (Nice) said the drug enzalutamide, also known as xtandi, should be considered for use in the treatment of men with hormone relapsed prostate cancer that has spread to other parts of the body.
Nice said in its draft guidance that it was pleased to recommend the drug, which is manufactured by Astellas Pharma, for patients who have few other treatment options left.
Better tests to define how aggressive a prostate cancer is needed, Cancer Research UK Cambridge Institute said, after it was reported that more than half of a group of men whose cancers were initially classified as slow-growing and confined turned out to have more dangerous tumours.
Urological surgeon Greg Shaw said:
This highlights the urgent need for better tests to define how aggressive a prostate cancer is from the outset, building on diagnostic tests like MRI (magnetic resonance imaging) scans, and new biopsy techniques which help to more accurately define the extent of the prostate cancer.
This would then enable us to counsel patients with more certainty whether the prostate cancer identified is suitable for active surveillance or not.
Whilst active surveillance would seem to be a safe approach for some men, nearly a third will end up needing surgery or radiotherapy within five years.